Objective: The aim of this study was to evaluate the association between insulin resistance and thyroid pathology in obese patients, and compare the results between insulin-resistant and noninsulin-resistant patients. Subjects and methods: Obese/nondiabetic patients, aged 18-70 years, attending the outpatient endocrinology service for 2 years were consecutively included. We evaluated the patients' fasting plasma glucose, insulin, homeostasis model assessment of insulin resistance index (HOMA-IR), thyroid-stimulating hormone (TSH), free thyroxine (FT4), antithyroperoxidase antibodies (TPO-Ab), antithyroglobulin antibodies (Tg-Ab), and thyroid ultrasound. Results: We included 82 patients with a mean age 44.21 ± 12.67 years. The thyroid disorders encountered and their prevalences were: hypothyroidism (14.6%, 95% confidence interval [CI] 8.6-23.8%), hyperthyroidism (1.2%, 95% CI 2.0-6.6%), goiter (28.0%, 95% CI 19.5-3.6%), thyroid nodules (35.4%, 95% CI 25.9-46.2%), and Hashimoto's thyroiditis (32.9%, 95% CI 23.7-43.7%). HOMA-IR correlated positively with TSH levels (r = 0.24, p = 0.028), and this correlation remained after adjustment for body mass index (BMI), waist/hip ratio (WHR), serum cortisol, subcutaneous fat thickness (SFT), visceral fat thickness (VFT), triglycerides, γ-glutamyl transpeptidase (GGT), and alanine aminotransferase (ALT) in multivariate regression analysis (b = 0.207, 95% CI, 0.09-0.385, p = 0.023). TSH levels were significantly higher in patients with HOMA-IR ≥ 2.5 than in those with HOMA-IR < 2.5 (2.03 µIU/mL, interquartile range [IQR] 1.59-2.69 µIU/mL) versus 1.59 µIU/mL, IQR 0.94-2.26 µIU/mL, p = 0.023). Conclusions: The most prevalent thyroid disorder in patients attending our endocrinology clinic for investigation of obesity was thyroid nodules. One in seven patients had hypothyroidism. Our findings suggest that TSH levels correlate with insulin resistance in obese patients. Arch Endocrinol Metab. 2017;61(6):575-83 
INTRODUCTION
T hyroid hormones have well-known effects on carbohydrate metabolism, including insulin resistance (IR), which is caused both by hyperthyroidism and hypothyroidism. However, the impact of thyroid hormones on metabolic syndrome (MS) and its main element, IR, in particular, are still unknown. Systemic effects of IR are complex. Among them, the metabolic effects are the most common and include decreased glucose tolerance, type 2 diabetes mellitus, hypercholesterolemia, hypertriglyceridemia, nonalcoholic fatty liver disease (NAFLD), central obesity, hypertension, "low-grade" chronic inflammatory status, oxidative stress, and increased cardiovascular risk.
The endocrine effects of IR are not completely known, although the involvement of IR in the etiopathology of polycystic ovary syndrome (POS) is well established. Lately, there has been increased interest in the effects of IR and MS on the thyroid (1-3). The association of IR and MS with thyroid diseases has been reported by several studies that have shown an increased incidence of hypothyroidism, autoimmune thyroiditis, thyroid nodules, and differentiated thyroid carcinomas along with other systemic malignancies (4, 5) . Patients with both POS and IR have been described as having an increased frequency of thyroid disorders such as hypothyroidism, Hashimoto's thyroiditis, and Graves' disease (6) . IR may play a role in the etiopathogenesis of thyroid disorders through different mechanisms. Similar to IGF-1, insulin is a growth factor with in vitro proliferative, antiapoptotic, angiogenic, and "mitogenic" effects on cultured thyroid cells (7, 8) . Hyperinsulinemia may increase the volume of the thyroid and lead to the development of thyroid nodules (9, 10) . Most obese patients with IR present metabolic liver disease as a consequence of disorders in lipid and glucose metabolism induced by hyperinsulinemia, which in turn may affect the hepatic T4 to T3 conversion and the feedback exerted by the free hormone fractions on TSH secretion (5, 11) . Additionally, IR increases the inflammatory response by stimulating adipocyte production of inflammatory cytokines. Oxidative stress is also increased in MS, and both are involved in the pathogenesis of carcinoma and autoimmune thyroid diseases (3, 4) . Hypertonia of the hypothalamic-pituitary-adrenal (HPA) axis, which is more pronounced in obesity, may also have an impact on thyroid function (12) .
The present study aimed at assessing the relationship between IR and pathologies of the thyroid by performing a morphofunctional thyroid evaluation of a representative sample of obese patients. A secondary objective was to analyze the differences between obese patients with and without IR. We also investigated the association between morning serum cortisol, thyroid function, and IR.
SUBJECTS AND METHODS

Patients
This was a cross-sectional, observational study using representative sampling. The cohort comprised all consecutive patients referred for obesity-related issues to the ambulatory of the Department of Endocrinology at the Infectious Diseases Hospital over a period of 2 years.
The inclusion criteria were a body mass index (BMI) > 30 kg/m 2 and age between 18-70 years. The exclusion criteria comprised a diagnosis of diabetes (history of diabetes or fasting glucose ≥ 125 mg/dL), thyroid disorders, psychiatric disorders, hepatic insufficiency, congestive heart failure, or refusal to participate in the study. All participants underwent complete clinical, laboratory, and ultrasonographic evaluations.
Prior to recruitment, informed consent was obtained from each patient. (16) .
Thyroid function was assessed with measurement of TSH and free T4 serum levels, while screening for Hashimoto's thyroiditis was done with determination of antithyroid peroxidase (TPO) and antithyroglobulin antibodies. Serum cortisol was measured at 8 a.m. in all patients to assess the HPA axis and evaluate the relationship between serum cortisol levels and BMI, WC, WHR, serum insulin, HOMA-IR, and thyroid function.
Ultrasound evaluation
Each participant was evaluated with thyroid ultrasound for assessment of thyroid volume and morphology and detection of goiter, nodules, and autoimmune thyroiditis. The ultrasound evaluations were performed on a DC-N3 Doppler ultrasound system (Mindray DS USA, Inc., Mahwah, NJ, USA) equipped with a 7.5 MHz linear transducer. We also performed abdominal ultrasound evaluations to detect the occurrence of hepatic steatosis and measured the subcutaneous fat thickness (SFT) and visceral fat thickness (VFT) using the same ultrasound equipment (Mindray DC-N3 Doppler) equipped with a 5 MHz convex transducer. Hepatic steatosis was defined as the presence of a diffuse, hyperechoic, and bright liver, with an increased echotexture when compared to the kidneys, vascular blurring, and deep attenuation of the ultrasonic beam. The occurrence of nonalcoholic steatohepatitis (NASH) was defined by the presence of a combination of imaging (hepatic steatosis on ultrasound imaging) and laboratory criteria (detection of increased transaminases levels after exclusion of other causes of secondary hepatic fat accumulation, such as significant alcohol consumption [> 30 g alcohol/day for men and > 20 g/day for women], other liver diseases [hepatitis B, C, and autoimmune hepatitis], use of steatogenic medications, or hereditary disorders) (17) .
The VFT was measured with the ultrasound probe located 1 cm above the umbilicus on the xiphoumbilical line in both longitudinal and transverse views and defined as the distance between the linea alba and the anterior wall of the aorta. The SFT was determined as the distance between the linea alba and the skin, with the transducer located 1 cm above the umbilicus. All patients were evaluated by the same radiologist.
Statistical analysis
All results were statistically analyzed using Excel (Microsoft, Redmond, WA, USA) and SPSS (SPSS, Inc., Chicago, IL, USA). The sample size was calculated based on a 0.1-0.3% prevalence of thyroid pathologies with a 95% level of confidence and ± 10% confidence interval (CI) length (3, 18) . Data with normal distribution were reported as mean ± standard deviation, and those without normal distribution as median (25 th -75 th percentiles [Q1, Q3]). Differences between groups were analyzed with Student's t test for independent samples in case of normally distributed quantitative variables, and the Mann-Whitney test for data without normal distribution. For qualitative data, chi-square test of Fisher's exact test was used. Pearson's correlation coefficient was applied to determine the linear relationship between two or more continuous quantitative variables, while Spearman's correlation coefficient was used to assess the relationship between several continuous quantitative variables with outliers or to assess nonlinear relationships.
In order to estimate the relationship between serum TSH levels and HOMA-IR values with multivariate analysis, we used multiple logistic regression. We adopted as the dependent variable the classification given by the HOMA-IR cutoff value and as independent variables all other continuous variables that correlated significantly with HOMA-IR in the univariate analysis. Considering that the relationship between HOMA-IR values and serum TSH levels was nonlinear, we adopted the classification given by the ratio between HOMA-IR values and TSH levels. Using a HOMA-IR cutoff value of 2.5, the patients were divided into two groups: obese and IR (HOMA-IR ≥ 2.5; Ob-IR) and obese without IR (HOMA-IR < 2.5; Ob-NIR).
RESULTS
Baseline characteristics
The study included 82 obese patients with a mean age of 44.21 ± 12.67 years, of whom 91.5% were women, Table 2 shows the frequency of thyroid disorders in the cohort. Thyroid nodules were among the most frequent morphological abnormalities, while one out of seven patients presented hypothyroidism. Analysis of the relationship between HOMA-IR and thyroid function
There was a positive correlation between HOMA-IR values and TSH levels (r = 0.24, p = 0.028) in the overall cohort (n = 82). TSH correlated positively with serum insulin (r = 0.23, p = 0.037). In contrast, no significant correlation was found between insulin, HOMA-IR, and thyroid volume. Table 3 presents an analysis of differences between the groups with HOMA-IR ≥ 2.5 and < 2.5 (Ob-IR and Ob-NIR, respectively). Patients with HOMA-IR ≥ 2.5 had significantly higher TSH levels than those with HOMA-IR < 2.5. Thyroid nodules were detected in 44.4% of the patients with HOMA-IR ≥ 2.5 compared with 24.3% of those with HOMA-IR < 2.5 (p = 0.058), thus showing a trend towards an association between both variables. Although patients with HOMA-IR ≥ 2.5 had an increased frequency of goiter and Hashimoto's thyroiditis, the difference was not significant (Table 3) Both groups also presented differences in metabolic parameters (BMI, WC, HC, SFT, VFT) and MS, which were significantly higher in patients with HOMA-IR ≥ 2.5 than in those with HOMA-IR < 2.5 ( Table 4) .
Analysis of the relationship between serum TSH levels and metabolic parameters
Serum TSH levels correlated positively with serum triglycerides levels (r = 0.30, p = 0.006) and negatively with serum HDL-cholesterol levels (r = -0.25, p = 002). There was a positive relationship between serum TSH levels and serum morning cortisol levels (r = 0.26, p = 0.02).
When we compared obese patients with and without hepatic steatosis in regards to thyroid dysfunction, we found no significant differences in TSH levels between both groups. Obese patients with NASH displayed significantly higher TSH values compared with those without NASH (Table 5 ). There were no significant differences in TSH levels between subjects with versus those without MS. 
DISCUSSION
The results of this study showed a significant positive correlation of HOMA-IR values with serum TSH levels among obese patients. Ob-IR patients had significantly higher TSH levels compared with Ob-NIR patients, although FT4 levels were comparable in both groups (Table 3) . These results are consistent with others reported in the literature (19, 20) . Increased TSH level could thus be hypothesized to be a metabolic consequence of obesity. The mechanisms by which IR may impact the thyroid are not completely understood. Recent evidence suggests that the main suspected mechanism is a possible relationship between thyroid hormones and the adipokines released by visceral fat, especially leptin (21, 22) . Leptin interferes with the negative feedback regulation of thyroid hormones and stimulates the hypothalamic-pituitary-thyroid axis to increase TSH secretion (23) . Production of leptin increases along with increased body fat, with visceral fat mass inducing and aggravating IR, while hyperinsulinemia stimulates the production of leptin (24) . Another hypothesis is that the metabolic hepatic disorder related to IR could impact the metabolism of thyroid hormones. Hepatic IR leads to increased glucose production and increased VLDL-cholesterol, aggravating hyperglycemia and hyperinsulinemia. IR increases the influx of free fatty acids (FFA) to the liver and de novo lipogenesis, leading to lipid accumulation in hepatocytes, which in the context of the inflammatory status and oxidative stress, increases lipid peroxidation and mitochondrial dysfunction, leading to NASH (25) . Consequently, metabolic liver damage can lead to impaired synthesis of thyroid hormones transport proteins (thyroxine-binding globulin [TBG] , albumin, and transthyretin), decreasing the transport of these hormones to target cells. Moreover, decreased type I 5'-deiodinase activity alters T4 to T3 conversion, which can stimulate TSH production by reducing the feedback of the thyroid hormones on the HPA (11, 26) . In support of the previous hypothesis, HOMA-IR correlated positively with liver markers (ALT and GGT) and obese patients with severe hepatic impairment (NASH) had significantly higher TSH levels than those without NASH (Table 5 ). Of note, we did not perform liver biopsy for histological confirmation of NASH, which may be considered one of our study's limitations.
As expected, HOMA-IR correlated positively with the degree of obesity (BMI) and visceral adipose tissue (WC, WHR, and VFT) and the Ob-IR group had significantly higher BMI, VFT, and WC values when compared with the Ob-NIR group (Table 4) . This fact supports the theory that obesity and particularly its visceral component should be considered the main causative factor in MS (27) . Macrophage infiltration with increased production of adipokines and cytokines (TNF-α, MCP-1, CRP, IL-1, IL-6, FFA, leptin, resistin) occurs at the level of visceral fat, leading to chronic "low-grade" inflammation and oxidative stress, which affect insulin signaling in target cells (and binding of insulin to its receptor) leading to IR and its systemic consequences (28) .
A comparison of both our study groups showed a significantly higher incidence of MS and uncontrolled hypertension among Ob-IR patients. Also, the OB-IR group had a higher frequency of liver disease (NAFLD/ NASH) than the Ob-NIR group (Table 4) .
Recent publications have suggested the occurrence of peripheral resistance to thyroid hormones secondary to the oxidative stress and inflammatory status related to IR, which would alter the transmembrane intracellular transport of thyroid hormone and its binding to nuclear receptors (29). Other possible assumptions are that the central hypertonia of the TRH-TSH axis in obesity is an adaptation to chronically increased caloric intake aiming at resetting the basal metabolism at a higher level. This results in increased T4 levels and T4 to T3 conversion by stimulation of the type 2 deiodinase (5'D2) activity in muscle and brown tissue to boost energy expenditure. This theory might also justify the higher TSH levels observed among obese patients (26) .
Our study has shown a positive correlation between serum TSH and cortisol levels, both of which correlated positively with HOMA-IR. No correlation was found between cortisol and FT4 levels, which is consistent with previously reported data in the specialized literature (30) .
Little is known about the HPA axis hypertonia involved in obesity and its relation to the TRH-TSHthyroid axis. Elevated serum cortisol may have peripheral and hepatic effects by decreasing the hepatic synthesis of TBG, affecting T4 to T3 conversion (decreasing the type 1 deiodinase [5'D1] activity), and stimulating the conversion of T4 into inactive reverse T3 (increasing the type 3 deiodinase [5'D3] activity). Elevated cortisol may also have a central impact since cortisol has an effect on TSH depression (31, 32) . Moreover, the serum cortisol measurements in our obese patients demonstrated a U-shaped association with BMI: patients with overweight and first-degree obesity showed normal or low morning serum cortisol, which increased along with the obesity (33) . These controversies are likely due to the increased peripheral metabolism of cortisol. Patients with obesity may display enhanced inactivation of cortisol by 5α-reductase or impaired reactivation of cortisol from cortisone by 11β-hydroxysteroid dehydrogenase type 1, resulting in activation of the HPA axis (34, 35) .
A negative correlation between serum TSH and cortisol levels has been reported for TSH cutoff values < 2.0 µUI/mL, while a positive correlation has been observed for cutoff values > 2.0 µUI/mL (30) . Similar to our results, other researchers have also reported a positive correlation of cortisol and TSH levels in euthyroid obese patients (36) .
Recent studies have shown that MS and its central factor (IR) are associated with increased thyroid volume, prevalence of thyroid nodules, and risk of systemic malignancies, including differentiated thyroid carcinomas (7, 37) .
Comparing both our groups with and without IR in regards to thyroid morphology, we observed a higher frequency of goiter (33.3% versus 21.6%) and thyroid nodules (44.4% versus 24.3%, p = 0.058) in the Ob-IR group, although without statistical significance. There were no significant differences in the incidence of Hashimoto's thyroiditis in the two groups.
We must note that the results obtained in our study derived from a population attending an Endocrinology Department for investigation of obesity, which explains the 10-fold higher prevalence of women over men in our cohort. As a consequence, the prevalence rates encountered cannot be generalized to the entire population of obese individuals. The female population is known to be the most interested group in investigating the causes of obesity, and multiple studies have been conducted exclusively in women (38) . Additionally, thyroid disorders are considered to be more common in women (39) . Due to limited financial resources, we calculated the sample size with an accurate CI of ± 10%. We consider this as a limitation of the study and recommend that further research should be conducted including a larger sample size.
The proliferative effect of insulin has been shown in vitro using cultured thyroid cells via the insulin receptors and IGF-1 receptor -both overexpressed in thyroid tumors as well as in non-thyroid tumors (breast, colon, liver). Hyperinsulinemia can, thus, determine an increase in thyroid volume, occurrence of thyroid nodules, and thyroid carcinogenesis (4, 8, 40) . Moreover, TSH is a major growth factor in the thyroid gland and a regulator of the expression other growth factors; TSH promotes the insulin/IGF-1 signaling pathway, while IGF-1 is actively involved in TSHmediated proliferation of thyrocytes (8, 41) . Patients with IR have higher TSH levels than those without IR and, as a consequence, a higher risk of proliferation of thyroid cells due to its morphogenic effect.
In conclusion, obese patients displayed a significantly positive correlation between HOMA-IR values and TSH levels. Our findings validate the cutoff value of 2.5 for HOMA-IR in regards to TSH levels, which was higher in obese patients with IR when compared with those without IR. Although serum cortisol correlated with HOMA-IR values and serum TSH levels, the correlation of HOMA-IR and TSH remained even after adjusting the cortisol's influence.
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